Dr. Karen Kelly, Associate Director for Clinical Research at UC Davis Comprehensive Cancer Center, met with GRACE to bring updates to our Lung Cancer...
Dr. Sandip Patel, Associate Professor of Medicine at the Moores Cancer Center, UC San Diego Health, joined GRACE to offer updates to our Lung Cancer...
Dr. Sandip Patel, Associate Professor of Medicine at the Moores Cancer Center, UC San Diego Health, joined GRACE to offer updates to our Lung Cancer...
Dr. Sandip Patel, Associate Professor of Medicine at the Moores Cancer Center, UC San Diego Health, joined GRACE to offer updates to our Lung Cancer...
Dr. Sandip Patel, Associate Professor of Medicine at the Moores Cancer Center, UC San Diego Health, joined GRACE to offer updates to our Lung Cancer...
A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect...
Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs...
The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show...
Guest post by Dr. Nate Pennell, a board certified medical oncologist at the Taussig Cancer Center at the Cleveland Clinic. He specializes in the...
As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.